Dr. Takeshi Shimamura
Dr. Takeshi Shimamura is a VST Assoicate Professor at University of Illinois at Chicago’s (UIC) College of Medicine in the Department of Surgery. For the past 7 years, his independent research program has focused on pre-clinically developing therapeutic approaches to overcome acquired and de novo resistance to targeted agents in non-small cell lung carcinoma (NSCLC). More specifically, his team is interested in dissecting the signaling mechanisms of NSCLC with an epithelial to mesenchymal transition (EMT) phenotype, which is associated with resistance to anti-neoplastic targeted agents. Dr. Shimamura’s interest in investigating the role of EMT in NSCLC drug resistance began during his postdoctoral fellowship in Dr. Geoffrey I. Shapiro’s laboratory at the Dana-Farber Cancer Institute (DFCI). At DFCI, he investigated the biology of kinase activating mutations in NSCLC and developed strategies to overcome acquired resistance to targeted therapies in NSCLC. In May 2019, Dr. Shimamura started a tenured associate professor position at UIC. Dr. Shimamura’s expertise in pre-clinical lung cancer translational research, particularly with genetically engineered mouse models, leads his research interest to delineate the role of CXCR7 in EMT and drug resistance.
Title: VST Associate Professor
College: College of Medicine
Program: Translational Oncology Program
Member Type:Research Member